Chris Zou

Interactions with Government officials regarding the awarding of any grant, contribution or other financial benefit. Interaction with Government of Canada officials in regards to the Hazardous Products Act particulary the Controlled Products Regulations; Hazardous Products Regulations and the Hazardous Materials Information Review Regulations. Interaction with Government of Canada officials in regards to consultations to implement Globally Harmonized System of Classification and Labelling of Chemicals as per Hazardous Products Act. Interaction with Government of Canada officials in regards to certification, modification and approval of BASF Canada’s portfolio, including pesticides, herbicides and other agricultural chemicals, under the Fertilizers Act and the Feeds Regulations Act. Interactions with responsible departments re Parliamentary review of the Canadian Environmental Protection Act and the Chemicals Management Plan Interactions with Government of Canada officials in regard to the Seed Regulatory Modernization (SRM) initiative.

Working with our Industry Associations (Innovative Medicines Canada and BIOTECanada) to provide industry recommendations on Canada's Biomanufacturing and Life Sciences Strategy, National Pharmacare, Intellectual property as well as pricing reforms (PMPRB) Science and Technology Strategy, advocating for the development of a Biopharma sector in support of more research & development in Canada. R&D requirements set forth through the Patent Medicines Pricing Review Board (PMPRB) Patent Medicines Pricing Review Board reforms, regarding both the revised regulations and draft guidelines Patented Medicines (Notice of Compliance) Regulations as it relates to regulation of intellectual property for therapeutic products. Novartis is working with our industry associations (Innovative Medicines Canada and BIOTECanada) to provide a written response to Guideline consultation process and will provide our own corporate submission. Patented Medicine Prices Review Board (PMPRB) Regulations as related to reporting requirements and pricing guidelines. Federal Public Drug Plans, with respect to the reimbursement of drug products for the Federal plan beneficiaries Federal Innovation agenda. Working with our Industry Associations (Innovative Medicines Canada and BIOTECanada) to ensure that innovative medicines, and our contribution to Research and Development in Canada are part of the consultation process in the development of this new innovation agenda. Canadian Agency for Drugs and Technologies in Health (CADTH), including Therapeutic Reviews and the Common Drug Review as it relates to reimbursement recommendations for decision-making process and framework.

Focus on girls' rights and youth leadership in Canada focused on addressing systemic barriers to gender equality in leadership in Canada and globally. Plan International Canada advocates for gender equality and children's rights. Our policy and advocacy spans a number of sectors, including, health, education, child protection, climate change, economic security, water and sanitation, emergencies and child participation.